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Abstract Lanreotide depot (LD; commercial name
Somatuline Depot) is an injectable, extended-release
formulation of the synthetic somatostatin analog (SSA)
lanreotide. In recent clinical trials, LD was found to be
suitable for self or partner administration, avoiding the
need to travel to a medical facility. The Somatuline Depot
for Acromegaly (SODA) study is an ongoing, multicenter,
observational study in the US investigating the efficacy,
safety, convenience and symptom relief provided by LD in
patients with acromegaly. Sub-analyses explore outcomes
according to who administered the injection: patient,
partner, healthcare provider (HCP) or a combination. Data
reported here reflect one year of patient experience.
Patients are eligible for inclusion if they have a diagnosis
of acromegaly, are treated with LD and can give signed
informed consent. Baseline data include patient demo-
graphics, previous acromegaly treatment and investiga-
tions, GH and IGF-I levels, LD dose and dose adjustment
frequency. Symptom frequency, injection pain and treat-
ment convenience are assessed using patient-reported
questionnaires. As of 18 April 2012, 166 patients had
enrolled in SODA. Most (72 %) achieved normal IGF-I
levels after 12 months of LD treatment. Disease control
was similar in self or partner injectors and in patients who
received injections from their HCP, although self or partner
injecting was deemed more convenient. LD was well-tol-
erated irrespective of who performed the injection. Self
injection led to more injection-site reactions, but this did
not increase the rate of treatment interruption. Acromegaly
symptoms remained stable. Biochemical, safety and con-
venience data support the clinical validity of injecting LD
at home.
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Introduction
Acromegaly is a rare disorder that results from excessive
production of growth hormone (GH), usually due to a
benign pituitary adenoma. Affecting approximately 40–125
people per million in the United States (US) [1], and pos-
sibly more [2–4], acromegaly is characterized by symp-
toms related to multiple body systems and increased risk of
all-cause mortality [5]. Treatment typically entails surgical
excision of the pituitary adenoma to normalize GH secre-
tion, and to relieve compression symptoms in cases of
larger tumor mass. However, complete tumor removal may
not be possible if, as often happens, adenomas are large at
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the time of diagnosis, or in occasional cases when surgery
is contraindicated or declined. As a result, over 50 % of
patients have active residual disease, defined by increased
levels of GH, and/or its physiological mediator, insulin-like
growth factor-1 (IGF-I), leading to persistent clinical
symptoms, impaired health-related quality of life and
increased mortality [6–8]. A recent systematic review of
the literature determined that mortality, morbidity and cost
are all higher in patients with biochemically uncontrolled
acromegaly than in those with GH levels \2.5 lg/L and
IGF-I normal for age and gender [9]. As such, patients with
uncontrolled disease typically receive pharmacological
therapy such as somatostatin analogs (SSAs), the GH
receptor antagonist pegvisomant or, less commonly,
dopamine agonists or radiotherapy, to further reduce the
symptoms and long-term consequences of unregulated GH
secretion [1, 10].
Lanreotide depot (LD) is a synthetic octapeptide SSA
that binds to somatostatin receptors Type 2 and—to a lesser
degree—Type 5, inhibiting GH secretion and reducing
IGF-I levels [11]. The long-acting, extended-release
aqueous-gel formulation lanreotide depot is known in the
US as Somatuline Depot [12], and as Somatuline Auto-
gel in the rest of the world. LD is approved in the US for
the long-term treatment of acromegaly in patients with
inadequate response, or contraindications, to surgery or
radiotherapy [12]. LD is supplied as a pre-filled syringe for
deep subcutaneous injection of 60, 90 or 120 mg, does not
require reconstitution, and was recently demonstrated in a
6-month clinical trial to be suitable for self or partner
administration thus avoiding travel to a medical facility
[13]. Whether LD may reliably be self-administered in the
real-world setting remains unknown.
The Somatuline Depot for Acromegaly (SODA) study
is an ongoing, multicenter, observational study in the US,
investigating the efficacy, safety, treatment convenience
and symptom relief provided by LD in patients with
acromegaly. Several post hoc sub-analyses have been
conducted, including differences in outcome based on who
administered the injection: patient, partner, healthcare
provider (HCP) or a combination of injectors. The data
reported in this manuscript reflect 1 year of patient expe-
rience in this ongoing study.
Patients and methods
Patients
Patients are eligible for inclusion in the SODA study if they
have a clinical diagnosis of acromegaly, are treated with
LD (including patients for whom LD is newly prescribed
and those switched from other agents) and are competent to
give signed informed consent. Those with symptomatic,
untreated gallstones or known sensitivity to SSAs are
ineligible. There is no limit on time from prior surgery or
radiation therapy and patients can be enrolled at any time
after starting the drug. Patients who have never received
any form of octreotide and those who start LD within
30 days prior to enrollment are considered treatment-naı¨ve.
All eligible patients are included in the study and continue
to receive LD as prescribed by their physician for the
duration of their participation. The day on which the con-
sent form is signed is considered the enrollment date.
Study design and assessments
The SODA study is carried out in academic and private
treatment centers in the US. Baseline characteristics
include patient demographics, previous acromegaly treat-
ment and investigations, and hormone levels (GH and IGF-
I). LD dose and frequency of dose adjustment are recorded
at every study visit after enrollment. As this is a non-
interventional, observational study, the frequency of study
visits, biochemical testing, radiological, echographic and
sonographic evaluation is determined by the treating phy-
sician, and thus not all data points are available for all
patients. Efficacy is assessed using serum IGF-I and GH
concentrations evaluated at either a central or local labo-
ratory with the recommended time points being at 3 and
6 months, then yearly. Investigators record whether the
levels are normal, elevated or low for their particular
hormone assay. Additional secondary analyses include
safety, symptom burden and treatment convenience. Safety
is evaluated by physical examination and recording of
adverse events (AEs), which are categorized in the protocol
as targeted (known to be associated with LD and other
SSAs, such as injection site reactions, bradycardia, diar-
rhea, or cholelithiasis) or unexpected. Symptom burden
(frequency), injection pain and treatment convenience are
assessed by administering the two patient-reported ques-
tionnaires to each patient. The symptom questionnaire asks
patients whether they experience specific symptoms
always/most of the time/sometimes/rarely/never; it is rec-
ommended to be administered at enrollment, 6, 12 and
24 months after enrollment, and every subsequent
6 months until study completion, or at interval visits if
these occur outside of the planned schedule. The conve-
nience questionnaire inquires about who administers SSA
injections, how long injections take to administer (includ-
ing travel time to reach the clinic, if necessary) and whe-
ther injections are convenient, painful and/or technically
difficult. It follows the same schedule as the symptom
questionnaire except that the first post-enrollment ques-
tionnaire is administered at 12 months. Questionnaires are
available in ‘‘Appendix’’.
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For this report, biochemical control (GH and IGF-I
levels) was analyzed using the 1-year completer popula-
tion, defined as all patients with IGF-I levels available at
enrollment and month 12 (n = 87). LD dose, symptom
control, pain and convenience were analyzed for all
patients who had the respective data available at enrollment
and after one year; as such, the observed data reflect dif-
ferent patient numbers in each group. Safety analyses were
conducted on all enrolled patients (n = 166). Data were
categorized according to who administered the LD injec-
tions: patient, partner, HCP or any combination of patient,
partner and HCP (the ‘Combination/other’ injector group).
Statistical analyses were primarily descriptive. Data
reported in this paper reflect a data cut on 18 April 2012.
Results
Patients
As of 18 April 2012, 166 patients had enrolled in SODA,
104 (63 %) from academic medical centers, and 62 (37 %)
from private practice sites, across 22 states. Baseline
characteristics of the enrolled population are presented in
Table 1. Acromegaly was caused by a pituitary adenoma in
almost all patients (98 %). The majority (80 %) had
undergone pituitary surgery, 20 % had received radiation
therapy and 123 subjects (74 %) had received previous
pharmacological treatment in the form of SSAs, pegviso-
mant or a dopamine agonist; 19 (11 %) had not received
any previous acromegaly treatment or had started
LD B30 days prior to enrollment (collectively considered
treatment-naı¨ve for this analysis).
IGF-I levels were elevated in half of the population (76/
153) at enrollment and 28 % (24/87) of 1-year completers.
The proportion of samples analyzed at local laboratories
was 80 % at enrollment and 73 % at 12 months; the
remaining samples were analyzed at a central laboratory.
The majority of patients were taking 90 mg LD (Table 2).
Almost all enrolled patients (95 %) received LD injections
every 28 days and one was receiving 120 mg at the
extended dosing interval of every 42 days or longer. More
patients received injections from their HCP (58/166; 35 %)
than from other sources; 16 % self-injected, and the
remaining 50 % were evenly split between those who had
injections administered by their partner and those who used
a combination of methods.
Thirty-three patients discontinued the study during the
first year, six due to personal choice, three for financial
reasons, two died (one congestive heart failure and one
cardiac arrest) and another 14 discontinued for other rea-
sons (including pregnancy, change of physician, normal lab
tests or breach of protocol). Eight were lost to follow-up.
Differences in discontinuation rates between injector sub-
groups were not significant.
Biochemical control: IGF-I and GH levels
In the 1-year completer population (n = 87), the majority
(63/87; 72 %) demonstrated biochemical control after
12 months, as evidenced by IGF-I levels below the upper
limit of normal (Fig. 1); there was no significant difference
between previously treated and treatment-naı¨ve patients.
IGF-I levels were normalized in a similar percentage of self
(13/15; 87 %) and partner injectors (16/18; 89 %) and a
somewhat lower proportion of subjects who received
injections from their HCP (18/27; 67 %) or a combination
of injectors (16/27; 59 %) (p = 0.05 between partner-
injectors and the combination/other group; all other pair-
wise comparisons were non-significant) (Fig. 1). However,
when both groups of ‘home injectors’ (self and partner
injectors) were compared with both groups of ‘office
injectors’ (HCP and combination/other groups), a signifi-
cantly greater proportion of home injectors had normalized
IGF-I levels after 12 months [29/33 (88 %) vs. 34/54
(63 %); p = 0.01 on Fisher’s Exact test]. Mean fasting GH
level after 12 months, based on data available in 50
patients, was 1.7 ± 2.2 ng/mL; levels were B 2.5 ng/mL
in 40/50 (80 %) patients and \1 ng/mL in 30/50 (60 %)
patients.
Lanreotide depot dosing
LD dose information was available for 146 patients at
12 months (Table 2). In total, 42 (29 %) had dose adjust-
ments in the first year of enrollment in the study. The
proportion of subjects taking a 90 mg dose decreased in the
first year while the proportion taking 120 mg increased,
representing a general trend towards dose increase. Dose
adjustment was most commonly prompted by elevated
IGF-I levels (24/42; 57 %; p = NS between groups); other
reasons included low IGF-I levels (9/42; 21 %), high GH
levels (7/42; 17 %) and other reasons (10/42; 24 %). As at
enrollment, the majority (89 %) were administering injec-
tions every 28 days after 12 months of treatment.
Symptoms and convenience
A total of 100 patients (100/166; 60 %) completed the
symptom questionnaire both at enrollment and 12 months.
At enrollment, tiredness was the most common symptom
(72/100; 72 %) followed by snoring (68/100; 68 %), pain
(64/100; 64 %), sweating (58/100; 58 %), and headache
(32/100; 32 %). After 12 months, all symptoms remained
stable in these 100 patients.
Pituitary (2014) 17:13–21 15
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There was a second questionnaire concerning pain and
convenience filled out by the patients. At enrollment, 33 %
(54/166) of the patients reported LD injections to be painless,
55 % (92/166) described them as mildly/moderately painful
and 11 % (19/166) found injections very/extremely painful.
Responses after 12 months of treatment with LD were sim-
ilar to those at enrollment. Convenience data (Fig. 2) indi-
cated that overall, for the 102 patients who completed this
questionnaire at both enrollment and month 12, 72 % (73/
102) of patients found LD very or somewhat convenient,
although HCP injection was considered less convenient than
self or partner injection at enrollment and at 12 months.
Adverse events
In all, 61 % (101/166) of patients reported at least one AE,
with minimal difference between injector subgroups. The
most common targeted AEs (occurring in C10 % of
patients) were arthralgia, headache and gastrointestinal
disturbances (Table 3). Injection site reactions were con-
siderably more common when patients injected themselves
than when they were injected by someone else [19 %
(5/26) self injectors versus 2 % (1/41) partner injectors;
p \ 0.05]. Eleven percent of patients (18/166) reported a
total of 41 serious AEs (SAEs). Cerebrovascular accident












Gender, % M/F 35/65 59/42 43/57 66/34 51/49
Mean age, years (range) 52 ± 12 (23–73) 52 ± 16 (22–84) 49 ± 17 (13–86) 49 ± 13 (25–73) 50 ± 15 (13–86)
Time since diagnosis, months (mean) 99 ± 77 65 ± 63 98 ± 117 96 ± 105 89 ± 98
Etiology of acromegaly, n (%)a
Pituitary adenoma 26 (100) 41 (100) 56 (97) 40 (98) 163 (98)
McCune-Albright syndrome 0 1 (2) 1 (2) 0 2 (1)
Otherb 0 0 1 (2) 1 (2) 2 (1)
IGF-I level measuredc (n) 25 36 52 40 153
High, n (%) 10 (40) 15 (42) 28 (54) 23 (58) 76 (50)
Normal, n (%) 14 (56) 21 (58) 23 (44) 16 (40) 74 (48)
Low, n (%) 1 (4) 0 1 (2) 1 (3) 3 (2)
Unknown, n (%) 1 (4) 5 (12) 6 (15) 1 (3) 13 (8)
Peak glucose-suppression GH level (n) 6 4 6 8 24
Median, ng/mL 1.1 0.7 2.5 2.0 1.8
Trough GH B2.5 ng/mL, n (%) 5 (83) 3 (75) 3 (50) 5 (63) 16 (67)
Trough GH B1 ng/mL, n (%) 3 (50) 3 (75) 2 (33) 3 (38) 11 (46)
Prior pituitary surgery, n (%) 24 (92) 29 (71) 44 (76) 36 (88) 133 (80)
Prior radiation therapy, n (%) 2 (8) 5 (12) 15 (26) 12 (29) 34 (20)
Prior medical therapy, n (%)d,e 20 (77) 28 (68) 45 (78) 30 (73) 123 (74)
SSA 15 (58) 19 (46) 39 (67) 24 (59) 97 (58)
Short-acting octreotide 0 1 (2) 12 (21) 2 (5) 15 (9)
Long-acting octreotide 15 (58) 18 (44) 27 (47) 22 (54) 82 (49)
Dopamine agonist 9 (35) 17 (42) 14 (24) 11 (27) 51 (31)
Pegvisomant 5 (19) 2 (5) 12 (21) 9 (22) 28 (17)
None (treatment-naı¨ve) 2 (8) 7 (17) 5 (9) 5 (12) 19 (11)
Given the non-interventional nature of the study, not all datapoints are available for all patients
GH growth hormone, GHRH growth-hormone releasing hormone, IGF-I insulin-like growth factor-1, SSA somatostatin analog
a Categories are not mutually exclusive; two subjects were categorized as having a GH-secreting macroadenoma and a pituitary adenoma; one
subject had a pituitary adenoma and McCune-Albright syndrome
b Pituitary enlargement with high IGF-I, suggesting a probable GHRH-secreting pinealoma
c The proportion of IGF-I samples analyzed centrally was 20 % at enrollment and 27 % at 12 months; the remaining samples were analyzed in
local institutional laboratories. Values determined to be high, normal or low by investigator
d Values based on case report forms which did not identify patients using lanreotide depot
e Therapies were not mutually exclusive
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(n = 3) was the most common SAE, followed by pneu-
monia, acute renal failure, and urinary tract infection
(n = 2 for each). In three patients, SAEs were considered
possibly related to LD treatment (depression/suicidal ide-
ation, atrial fibrillation, cluster headache). Both deaths
were considered unrelated to treatment by the investigator.
Discussion
In this real-world, observational study in patients with active
acromegaly treated with LD, alone or as combination therapy,
most (72 %) patients achieved normal IGF-I levels after
1 year, indicating attainment of biochemical disease control.
Approximately one-third of patients required LD dose
adjustment during the year, typically an increase from 90 to
120 mg due to persistently elevated IGF-I levels. The per-
centage of patients achieving biochemical control in this study
is higher than has generally been reported previously with
SSAs [14], and likely reflects an enrollment bias since subjects
who were poorly or non-responsive to LD are less likely to be
enrolled and/or to continue receiving LD in this real-life study.
Our data were too few to allow comparison of response rates
between treatment-naı¨ve and previously treated subjects.
More importantly, disease control was similar in those who
self or partner injected when compared to patients who always
received injections from their HCP. Furthermore, comparison
of exclusively home injectors (patient or partner only) with
patients who received office injections revealed that a sig-
nificantly greater proportion of exclusively home injectors
achieved biochemical control after 1 year of LD treatment,
which may reflect a tendency of patients who respond better to
visit the physician’s office less often. In conjunction with
stable symptoms, good tolerability, and data indicating that
self and partner injecting were more convenient than injec-
tions administered by a HCP, these data support the clinical
validity and lifestyle benefits of injecting LD at home. The
only AE that occurred with greater frequency among self
Table 2 Lanreotide depot dose (n, %) at enrollment and after 12 months of treatment
Patient always Partner always HCP always Combination/other
Dose at enrollment (mg) n = 26 n = 41 n = 58 n = 41 All patients
(n = 166)
60 1 (4) 6 (15) 11 (19) 9 (22) 27 (16)
90 18 (69) 24 (59) 29 (50) 23 (56) 94 (57)
120 7 (27) 11 (27) 18 (31) 9 (22) 45 (27)
Dose at 12 months (mg) n = 23 n = 38 n = 50 n = 35 All patients
(n = 146)
60 1 (4) 6 (16) 7 (14) 7 (20) 21 (14)
90 10 (44) 19 (50) 21 (42) 12 (34) 62 (43)
120 12(53) 13 (34) 22 (44) 15 (43) 62 (43)
Fig. 1 IGF-I levels after 12 months’ treatment with lanreotide depot
(n = 87). The ‘Combination/other’ group comprises patients who
received injections from any combination of injectors [self, partner,
(HCP)]
Fig. 2 Self-reported convenience of lanreotide depot according to
who injected the treatment. The ‘Combination/other’ group comprises
patients who received injections from any combination of injectors
[self, partner, healthcare provider (HCP)]
Pituitary (2014) 17:13–21 17
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injectors than other groups was injection site reactions, which
were not associated with a higher rate of withdrawal from the
study.
Finding an alternative to visiting the HCP’s office may be
particularly important for patients who are busy, limited in their
mobility, or unable to easily access a local clinic for injections.
In addition to improving convenience, injection at home may
reduce direct (transportation, parking) and indirect (time away
from work; time spent by HCPs administering treatment) costs
to the patient and their healthcare system. Data from other
therapy areas in which treatment has traditionally been
administered by HCPs suggest that injection at home can lead to
similar or superior treatment adherence and quality of life
compared with HCP injections when injectors are competent in
the required techniques [15–18]. Such findings lend weight to
strategies that move beyond the typical reliance on HCP-only
injections to include partners and patients themselves.
The validity of self/partner injection of LD has been dem-
onstrated in two non-randomized, open-label controlled studies
in acromegaly patients, one in the US (n = 59) [13] and one in
the UK (n = 30, 15 receiving home injections) [19], both of
which showed that injections could be correctly administered
by self/partner without compromising efficacy or safety in most
patients. In the UK study, 14/15 (93 %) patients who elected to
receive home injections were able to successfully inject LD
without supervision, as determined by HCP confirmation of
accurate injection technique and maintenance of biochemical
(IGF-I and GH) control for the 40-week duration of the study. In
the US study, 33/59 (56 %) patients switched from octreotide
LAR (injected by an HCP) to self- or partner-injected LD [13].
According to their HCPs, all 41 patients and 18 partners cor-
rectly administered LD injections by week four. While the UK
and US studies recruited patients treated primarily at academic
centers who were amenable to enrolling in a clinical trial, the
SODA study includes a more heterogeneous patient population
treated at both private and academic centers. Our findings
therefore corroborate and extend the aforementioned study
data, providing support for the validity of self or partner
injecting in the real-world clinical environment.
The SODA study has a number of limitations. Firstly, it is an
observational study and not a randomized controlled trial. As
such, the causative role of LD on the reported outcomes is hard
to determine or quantify. Secondly, an enrollment bias toward
SSA-responsive patients is evident. Thirdly, the SODA popu-
lation is highly heterogeneous due to enrollment at different
stages of disease and treatment. Therefore, while the results
provide a real-life snapshot of the SODA patient population at
1 year, the conclusions that can be drawn with respect to par-
ticular patient groups are limited. Finally, selection bias among
treating physicians toward prescribing this medication for
patients who are more likely to successfully self-administer the
drug cannot be excluded. Such limitations notwithstanding,
these 1-year data suggest that administration of LD at home by
self or partner provides similar biochemical control to injec-
tions administered in the healthcare provider’s office, with
similar tolerability and greater convenience. Longer-term data
and/or data from controlled trials will be necessary to corrob-
orate these findings.
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Table 3 Targeted AEs reported
by C10 % of all patients










other (n = 41)
All patients
(n = 166)
Number of patients with
C1 targeted AE (n, %)
15 (58) 23 (56) 30 (52) 23 (56) 91 (55)
Targeted AEs
Arthralgia 4 (15) 9 (22) 17 (29) 6 (15) 36 (22)
Headache 8 (31) 10 (25) 9 (16) 9 (22) 36 (22)
Diarrhea 1 (4) 12 (29) 8 (14) 11 (27) 32 (19)
Abdominal pain 2 (8) 10 (24) 10 (17) 9 (22) 31 (19)
Nausea 0 10 (24) 9 (16) 5 (12) 24 (15)
Constipation 3 (12) 4 (10) 8 (14) 7 (17) 22 (13)
Flatulence 2 (8) 7 (17) 4 (7) 8 (20) 21 (13)
Injection site reaction 5 (19) 1 (2) 4 (7) 3 (7) 13 (8)
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